Ozempic, Wegovy and other GLP-1s shown to reduce alcohol-related hospitalizations

A recent study conducted by the University of Eastern Finland and Karolinska Institutet in Sweden has revealed that GLP-1 drugs like Ozempic, Wegovy, and Victoza may have a positive impact on individuals with alcohol use disorder (AUD). These drugs, which contain semaglutide or liraglutide, are commonly prescribed to manage type 2 diabetes and obesity. Previous research has indicated that individuals taking GLP-1 agonists report a decrease in alcohol consumption.

The study analyzed data from 228,000 individuals in Sweden with AUD, ranging in age from 16 to 64. It was found that those with AUD, obesity, and type 2 diabetes who were taking GLP-1 medications had a significantly lower risk of being hospitalized for alcohol or substance abuse-related conditions. Participants who were prescribed semaglutide showed a 36% lower risk, while those on liraglutide had a 28% lower risk.

Interestingly, the study also compared the effectiveness of GLP-1 drugs to naltrexone, a commonly used medication for alcohol use disorder. The findings revealed that GLP-1 agonists were more effective in reducing alcohol-related hospitalizations compared to naltrexone.

Lead study author Markku Lähteenvuo, a docent of forensic psychiatry at the University of Eastern Finland, emphasized the potential of GLP-1 drugs in treating alcohol and substance use disorders. He noted that while the study results are promising, further validation through randomized controlled trials is necessary.

Dr. Sue Decotiis, a weight-loss doctor in New York City, highlighted the existing research supporting the role of GLP-1 drugs in reducing alcohol intake. She mentioned that a significant number of her patients on semaglutide and tirzepatide reported a decreased desire to consume alcohol. Additionally, she mentioned a new weight-loss drug, Retatrutide, manufactured by Eli Lilly, which is believed to be even more effective in combating alcohol addiction.

It is estimated that approximately 28.9 million individuals aged 12 and older in the United States have AUD. While Novo Nordisk, the maker of Ozempic and Wegovy, acknowledged the importance of independent research on their products, they clarified that these drugs are not indicated for the treatment of addiction-related illnesses.

In conclusion, the study’s findings suggest that GLP-1 drugs like Ozempic, Wegovy, and Victoza may hold promise in reducing the risk of hospitalization for individuals with AUD. Further research is needed to fully understand the potential benefits of these medications in managing alcohol and substance use disorders.